Quarterly ResultMay 19, 2026, 05:07 PM
Akari Therapeutics Q1 Net Loss $14.46M; $12.13M Impairments
AI Summary
Akari Therapeutics Plc reported a significant net loss of $14.455 million for the three months ended March 31, 2026, a substantial increase from $3.705 million in the prior year. The loss was primarily driven by impairment charges totaling $12.130 million on goodwill and other intangible assets. The company also disclosed a going concern warning due to its accumulated deficit of $279.0 million and insufficient cash to fund operations for the next year. Additionally, Akari completed an ADS ratio change and regained compliance with Nasdaq's minimum bid price requirement.
Key Highlights
- Akari Therapeutics reported a net loss of $14.455 million for Q1 2026, up from $3.705 million in Q1 2025.
- The company recorded an $8.430 million impairment loss on goodwill in Q1 2026.
- An impairment loss of $3.700 million on other intangible assets was recognized in Q1 2026.
- Cash balance decreased to $2.768 million as of March 31, 2026, from $5.203 million at December 31, 2025.
- Total current assets were $3.589 million as of March 31, 2026, down from $5.462 million.
- Accumulated deficit increased to $279.005 million as of March 31, 2026.
- Total shareholders' equity decreased to $14.380 million from $28.328 million.
- The company changed its ADS ratio from 1:2,000 to 1:80,000 ordinary shares and regained Nasdaq compliance.
Price Impact
More from AKTX